KR101728384B1 - Composition for enhancing immune activity comprising milk protein with high content of organic copper or iron as an active ingredient and preparation method thereof - Google Patents

Abstract

It has been found that the addition of water to a mixed powder of whey powder and water-soluble copper or iron powder to heat-treat the copper-enriched copper-rich or iron-enriched iron-rich protein not only enhances the bioavailability of the mineral, Thereby increasing the number of immune cells and natural killer (NK) cells that are primarily resistant to the entry of pathogenic microorganisms such as macrophages, neutrophils, and monocytes in the blood, _H-positive T cells (helper T-cell) and CD8-positive sikimyeo increase the number of T _C cells (cytotoxic T-cell), activated macrophages (activated macrophage) tumor immune-related cytokines secreted by necrosis factor -α ( TNF-α) and interleukin-1β (IL-1β), thereby exhibiting an immunostimulating activity. Therefore, the active ingredient of the immunoconjugation food composition or the immunomodulating pharmaceutical composition Can be used as

Description

TECHNICAL FIELD The present invention relates to an immunoconjugate composition comprising an organic copper-copper or iron-enriched milk protein as an active ingredient and a method for preparing the same,

The present invention relates to a composition for enhancing an immune response comprising an active ingredient of copper-on-iron or iron-enriched milk protein as an active ingredient. The composition for enhancing immunity can be used as an active ingredient of a food composition for immunity enhancement or a pharmaceutical composition for enhancing immunity.

Korean Patent No. 1025272 discloses that the bioavailability of organic minerals such as calcium, iron, selenium and zinc, including hydrolyzed sericin and its associated minerals, is significantly better than that of inorganic minerals.

Korean Patent No. 1306931 discloses that an organic calcium-enriched milk protein obtained by heat-treating a mixture of non-sterilized whey and water-soluble calcium has excellent bioavailability and thus exhibits osteoporosis prevention and therapeutic effects.

However, it has been found that the inventive copper oxyapatite or iron-enriched hardened protein of the present invention prepared by mixing whey powder with water-soluble copper or iron powder and then heat-treating the present invention not only improves bioavailability of minerals, The number of immune cells and natural killer (NK) cells that primarily resist the invasion of pathogenic microorganisms such as macrophage, neutrophil and monocyte in the blood is increased and the number of lymphocytes in the lymph nodes CD4-positive T _H cells (helper T-cells) and CD8-positive T _C cells (cytotoxic T-cells), and the immune-related cytokine secreted from activated macrophages, tumor necrosis factor- (TNF-α) and interleukin-1β (IL-1β), and thus the present invention has been completed.

It is an object of the present invention to provide a composition for enhancing immunity comprising an organotinized copper or iron-fortified milk protein as an active ingredient.

It is another object of the present invention to provide a method for producing an organochlorine copper or iron-enriched milk protein having an immunostimulating activity.

In order to attain the above object, the present invention relates to a method for producing a fermented milk of copper or iron-enriched hardwood produced by adding water to a mixed powder obtained by mixing whey powder and water-soluble copper or iron powder and heating at 70 to 100 ° C for 10 minutes to 40 hours As an effective ingredient.

The whey powder may be a non-demineralized whey powder or a demineralized whey powder.

The water-soluble copper or iron powder may be a sulfate or a chloride of copper or iron.

The composition for enhancing immunity may be a food composition for enhancing immunity or a pharmaceutical composition for enhancing immunity.

The present invention also relates to a method for producing a fermented milk, comprising the steps of: mixing whey powder with aqueous copper or iron powder; And adding water to the mixed powder and heating the mixture at 70 to 100 ° C for 10 minutes to 40 hours. The present invention also provides a method for producing an iron-enriched copper or iron-rich protein having an immunostimulatory activity.

The organotinized copper or iron fortified milk protein of the present invention is useful as an immunocompetent and natural killer (NK) cell primarily resistant to the invasion of pathogenic microorganisms such as macrophage, neutrophil, monocyte, increasing the number of and, CD4-positive T _H cells (helper T-cell) and CD8-positive T _C cells sikimyeo increase the number of (cytotoxic T-cell), activated macrophages (activated macrophage) immune secretion in the relevant in the lymph nodes (TNF-a) and interleukin-l [beta] (IL-l [beta]) which are cytokines and exhibit immune enhancing activity.

FIG. 1A is a graph showing the distribution of macrophages, neutrophils and mononuclear cells in blood of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1B is a graph showing the distribution of NK cells and NKT cells in blood of a mouse administered with calcium-enriched calcium-rich milk (Ca-WPS) by a flow cytometer (FACS).
1C is a graph showing the distribution of macrophages, neutrophils and mononuclear cells in a lymph node of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1D is a graph showing the distribution of CD8 T cells in a lymph node of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1E is a graph showing the distribution of CD4 T cells in a lymph node of a mouse administered with calcium-enriched milk protein (Ca-WPS) by a flow cytometer (FACS).
FIG. 1F is a graph comparing secretion amounts of TNF-a and IL-1b, which are cytokines expressed in macrophages of mice treated with calcium-enriched calcium-rich milk (Ca-WPS), with inorganic calcium and whey powder (WPS).
FIG. 2A is a graph showing the distribution of macrophages, neutrophils, and mononuclear cells in the blood of a mouse treated with copper-enriched copper-rich protein (Cu-WPS) by a flow cytometer (FACS).
FIG. 2B is a graph showing the distribution of NK cells and NKT cells in blood of a mouse administered with copper-enriched copper-rich protein (Cu-WPS) by a flow cytometer (FACS).
FIG. 2C is a graph showing the distribution of macrophages, neutrophils and mononuclear cells in a lymph node of a mouse administered with copper-enriched copper-rich protein (Cu-WPS) by a flow cytometer (FACS).
FIG. 2d is a graph showing the distribution of CD8 T cells in a lymph node of a mouse treated with copper-enriched copper-rich protein (Cu-WPS) by a flow cytometer (FACS).
FIG. 2E is a graph showing the distribution of CD4 T cells in a lymph node of a mouse administered with copper-enriched copper-rich protein (Cu-WPS) by a flow cytometer (FACS).
FIG. 2f is a graph comparing secretion amounts of TNF-a and IL-1b, which are cytokines expressed in macrophages of mice treated with copper-enriched copper-rich protein (Cu-WPS), with inorganic copper and whey powder (WPS).
FIG. 3A is a graph showing the distribution of macrophages, neutrophils, and mononuclear cells in the blood of a mouse administered with an iron-rich iron-rich protein (Fe-WPS) by a flow cytometer (FACS).
FIG. 3B is a graph showing the distribution of NK cells and NKT cells in the blood of a mouse to which iron oxide-enriched milk protein (Fe-WPS) was administered by flow cytometry (FACS).
FIG. 3c is a graph showing the distribution of macrophages, neutrophils and mononuclear cells in a lymph node of a mouse administered with an iron-rich iron-rich protein (Fe-WPS) by a flow cytometer (FACS).
FIG. 3D is a graph showing the distribution of CD8 T cells in a lymph node of a mouse administered with an iron oxide-enriched milk protein (Fe-WPS) by a flow cytometer (FACS).
FIG. 3E is a graph showing the distribution of CD4 T cells in a lymph node of a mouse administered with an iron-rich iron-rich protein (Fe-WPS) by a flow cytometer (FACS).
FIG. 3f is a graph comparing the secretion amounts of TNF-a and IL-1b, which are cytokines expressed in macrophages of mice administered with the iron oxide-enriched milk protein (Fe-WPS), with that of inorganic iron and whey powder (WPS).

Hereinafter, the present invention will be described in detail.

The present invention relates to a method for improving immunity using an organochlorine-containing copper or iron-reinforced milk protein prepared by adding water to a mixed powder obtained by mixing whey powder and water-soluble copper or iron powder and heating the mixture at 70 to 100 ° C for 10 minutes to 40 hours The present invention also relates to a method for producing a fermented milk, comprising mixing a whey powder and an aqueous copper or iron powder; And adding water to the mixed powder and heating at 70 to 100 DEG C for 10 minutes to 40 hours. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing an iron-enriched copper or iron-

The whey powder may be a non-demineralized whey powder or a demineralized whey powder. The milk protein content of the whey powder is 10 to 20% by weight. For example, the milk protein content may vary depending on the kind of the raw material, the manufacturing method and the manufacturer, but generally 12 to 15% by weight of the non-desalted whey powder and 14 to 17% by weight of the demineralized whey powder are included.

The water-soluble copper or iron powder may be a sulfate or a chloride of copper or iron. For example, the water-soluble copper powder may be a copper sulfate powder, and the water-soluble iron powder may be a ferrous sulfate powder.

When chlorides or sulfates are used as the water-soluble copper or iron powder, the content of chlorine ions or sulfate ions increases as the amount of copper or iron organocarbons increases. These increased chlorine ions or sulfate ions can be simply removed by washing with water. For example, the concentration of the sulfate ion may be lowered to a harmless level by repeating 1-5 times using 0.5 to 10 times of the volume of water used to dissolve the copper sulfate, preferably 1 to 2 times of water have. The washing can be carried out by adding a suitable amount of water and centrifuging to remove the supernatant, for example, centrifuging at 500 to 50,000 rpm for 1 to 60 minutes. The centrifugation is carried out at room temperature without setting a temperature condition , But can be performed by setting the temperature constant to 25 DEG C or lower.

The mixing ratio of the whey powder and the water-soluble copper or iron powder can be adjusted depending on the content of copper oxides or organo-iron oxides in the copper or iron-enriched milk protein to be produced. For example, 1 to 100 parts by weight of water-soluble copper or iron powder may be mixed with 100 parts by weight of the whey powder.

The amount of water to be mixed into the mixed powder of the whey powder and the water-soluble copper or iron powder may be adjusted to an amount necessary for dissolving the mixed powder, and for example, 200 to 1500 parts by weight may be mixed with 100 parts by weight of the whey powder .

After adding water to the mixed powder, the mixture is stirred at 100 to 500 rpm for 5 to 60 minutes to dissolve, and then the mixture is heated at 70 to 100 ° C, preferably at 80 to 90 ° C for 10 minutes to 40 hours, And heated for 60 minutes to produce an organochlorine-rich copper or iron-rich milk protein.

The composition for enhancing immunity may be a food composition for enhancing immunity or a pharmaceutical composition for enhancing immunity.

As used herein, the term " comprising as an active ingredient " means that the inventive copper or iron-enriched hardened protein of the present invention contains an amount sufficient to exhibit immunostimulatory activity. The composition for immunity enhancement of the present invention preferably comprises 0.1 to 50% by weight of the above-described copper or iron-enriched protein of iron ore on the basis of the total weight of the composition, but is not limited thereto.

The pharmaceutical composition for enhancing immunity of the present invention can be utilized as an adjuvant for treating cancer diseases or vaccines for immunization which is required for immunotherapy.

The pharmaceutical compositions may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of medicaments.

The pharmaceutical compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to conventional methods. Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may be formulated into the compositions of the present invention with at least one excipient such as starch, calcium carbonate, (sucrose), lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a suppository base, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol gelatin and the like can be used.

The pharmaceutical composition may be administered orally or parenterally. Any parenteral administration method may be used, and systemic administration or topical administration is possible, but systemic administration is more preferable, and intravenous administration is most preferable.

The preferred dosage of the pharmaceutical composition will vary depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the pharmaceutical composition may be administered at a dose of 0.01 to 200 占 퐂 / kg per day, preferably 1 to 20 占 퐂 / kg, based on the recommended amount of copper or iron, based on the content of copper or iron good. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In addition, the composition of the present invention can be used as a food composition for an assisted diet of a cancer patient as well as a general person including an elderly person who needs immunity enhancing activity.

In the above food composition, there is no particular limitation on the kind of food. Examples of foods to which the above substances can be added include dairy products including dairy products, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, all of which include health functional foods in a conventional sense.

The organotinized copper or iron fortified milk protein may be added directly to the food or used with other food or food ingredients, and may be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). Generally, the amount of the compound in the health food may be 0.1 to 90 parts by weight of the total food. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

In the case of producing a beverage, there are no particular restrictions on the other components other than those containing the above-mentioned organotitanated copper or iron-fortified milk protein as an essential ingredient at the indicated ratio, and various flavors or natural carbohydrates, . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 of the composition of the present invention.

In addition to the above, the organotinized copper or iron fortified milk protein of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate, etc.) Alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. In addition, the organotinized copper or iron fortified milk protein of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.

Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Preparation Examples. However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples and Production Examples.

Preparation Example 1: Preparation of organotinized minerals

The non-desalted whey powder (hereinafter referred to as "WPS", 14% by weight protein) of Lacto Korea was used as the whey powder, and calcium chloride (CaCl 2 .H 2 O), calcium chloride Ferrous sulfate (FeSO4 · 7H₂O) was used for the production of organic iron (FeSO4 · 7H₂O), and copper sulfate (CuSO₄ · 7H₂O) was used for the production of organic copper.

The WPS and inorganic minerals were mixed in a weight ratio of 5: 1 so as to be mixed well. Then, distilled water having twice the weight of WPS was added thereto four times, followed by vigorous reaction for 30 minutes, followed by heating to 80 DEG C and reaction at 150 rpm for 30 minutes. After the reaction was completed, the reaction mixture was cooled at room temperature, centrifuged at 4000 rpm for 20 minutes at 25 ° C, and the supernatant was removed. The precipitate was washed three times with water of about 3 times the volume of the precipitate. The washed precipitate was spray dried and pulverized. The organotinized calcium-fortified milk protein and Ca-WPS, respectively, were named as Cu-WPS and Fe-WPS, respectively.

Experimental Example 1: Mineral analysis of organic-mineralized milk-fortified milk protein

The mineral content of Preparation Example 1 was analyzed by ICP method and shown in Table 1.

division WPS Ca-WPS Fe-WPS Cu-WPS Calcium (ppm) 3,111 38,880 10,990 5,757 Copper (ppm) ND 0.44 10 49,890 Iron (ppm) 1.3 25 19,120 35 Zinc (ppm) ND 3.55 7.4 21 Selenium (ppm) ND ND 11 2.48

* ND is not detected

EXPERIMENTAL EXAMPLE 2: Confirmation of Immune Enhancement Effect by Animal Experiment

1. Breeding and classification of experimental animals

Five week old Balb / C male rats (ORIENTBIO Inc., Korea) were purchased and weighed and weighed. The body weight was divided into five groups, WPS group and organically fortified mineral fortified milk protein group. Organic mineralized fortified milk protein was divided into high concentration, medium concentration and low concentration by concentration. 3 ~ 4 rabbits were kept at 20.0 ~ 25.0 ℃ temperature, 41.2 ~ 58.5% relative humidity and 150 ~ 300Lux light intensity. And they were kept in accordance with the Guideline for Breeding of Chonnam National University Medical School.

2. Organic mineral fortified milk protein dosage determination

The daily intake of minerals according to the Food and Drug Administration's safety standards is shown in Table 2.

division Adult (based on 60kg) Mouse (based on 20g) calcium 210-800 mg 70-266 [mu] g Copper 0.45-7.5 mg 0.15-2.5 [mu] g iron 4.5-45 mg 1.5-5 [mu] g

The high concentration, medium concentration and low concentration were calculated in consideration of the minerals content of the organo-mineralized milk-derived milk protein of Table 1 within the range not exceeding the standard of the above-mentioned food service administration, and the intake per kg per kg , The daily intakes of the mice were calculated on the basis of the body weight of 20 g, and the daily dose of the mice was determined as shown in Table 3.

division WPS Ca-WPS Cu-WPS Fe-WPS High concentration 260 [mu] g 260 [mu] g 2.32 [mu] g 5 [mu] g Medium concentration - 168 [mu] g 1.2 [mu] g 3.1 [mu] g Low concentration - 70 [mu] g 0.8 [mu] g 1.2 [mu] g

3. Experimental Method

1) Feed

Feeds were fed with animal feed (Rodent diet 2918C; Harlan Teklad, Indianapolis, IN, USA) and diet and beverages were fed free. Body weights were measured twice before the start of treatment and after 6 weeks.

2) Blood collection and tissue extraction

Each group was anesthetized with isoflurane and the blood was collected from the abdominal vein. Blood was collected and lymph nodes were collected.

3) Immunocytochemical analysis of blood

The blood sample is by 5 minutes centrifugation at 500 xg separate the serum, the control did not stain by dividing each one by 1x10 ⁶ cells using a hemacytometer, CD3, CD122, CD8a, and stained with CD4 marker antibodies and flow cytometry (FACSAria) Were used for immunocytochemical analysis. During flow cytometry, living cells were gated to measure cells stained with live intracellular marker antibodies. The macrophage, neutrophil and mononuclear cell distribution is the area indicated by the red arrow in the unstained sample.

In addition, NK cells and NKT cells were analyzed by gating P4 labeled on unstained samples. NK cells are distributed on the upper left side, and NKT cells are on the upper right side.

4) Immunocytochemical analysis of lymph nodes

The collected lymph nodes were carefully dissected from the mesh of 100 pore size to separate the cells. The cells were separated by centrifugation and counted with a hemacytometer. The cells were stained with 1 × 10 ⁶ cells in each well and stained with non-stained control, CD3, CD122, CD8a, CD4 marker antibody and analyzed by immunocytochemistry using a flow cytometer (FACSAria) In flow cytometry, living cells were gated to measure cells stained with a living intracellular marker antibody.

5) Measurement of cytokine secretion ability

(IL-1β, TNF-α) secreted from the culture supernatant were measured after the intraperitoneal macrophages were orally administered to the mice, which were orally administered with the mineral minerals, WPS, and the organo-mineralized milk protein. Non-adherent cells were removed and only adherent cells were obtained and cultured in 10% -FBS RPMI 1640, 37 ° C, 5% CO2 incubator (Sanyo) for 48 hours. The amount of IL-1β and TNF-α accumulated in the culture supernatant was measured by ELISA cytokine kit (R & Dsystem, USA).

4. Experimental results

1) Distribution of macrophages, neutrophils and mononuclear cells in blood

The macrophage, neutrophil, and monocyte populations in the blood of mice treated with calcium-enriched calcium-rich milk (Ca-WPS) did not show any significant difference compared to mice administered with WPS only, .

In the Cu-WPS-treated group, there was a significant difference in the macrophage, neutrophil and monocyte populations compared with the WPS-only mice, and it was particularly high in the group administered with 1.2 μg (FIG. 2a).

The macrophage, neutrophil, and monocyte populations of the mice treated with the iron-rich iron-rich milk protein (Fe-WPS) were significantly different from those of the WPS-only mice and slightly higher in the 1.2 μg 3a).

2) NK cell distribution of blood

The distribution of NK cells and NKT cells in the blood of mice treated with calcium-enriched Ca-enhanced milk (Ca-WPS) showed no significant difference compared to mice administered with WPS alone, ).

In the Cu-WPS-treated group, the NKT cells did not show a significant difference compared to the WPS-treated mice, but increased in the NK cell population (FIG. 2B).

In the group treated with the iron-rich iron-rich protein (Fe-WPS), there was no significant difference in the NKT cells, but it was increased in the NK cell population (FIG.

3) Distribution of macrophages, neutrophils and monocytes in lymph nodes

The macrophage, neutrophil, and monocyte populations of the lymphocytes treated with calcium-enriched Ca-enhanced milk protein (Ca-WPS), as well as blood, did not show a significant difference compared to mice administered with WPS only (FIG.

(Cu-WPS) group than in the group treated with WPS only (Fig. 2C).

(Fe-WPS) group significantly increased compared to mice administered only WPS (FIG. 3c).

4) Distribution of CD8 and CD4-positive T cells in lymph nodes

The CD8 + T cell population in the lymph nodes of the mice treated with the calcium-enriched Ca-enhanced milk protein (Ca-WPS) showed a tendency to decrease compared to the mice treated with WPS only (Fig. 1d) (FIG. 1e) in the CD4 + T cell population.

In the group administered with Cu-WPS, the CD8 + T cell population showed a tendency to increase as compared to the group treated with WPS only (Fig. 2d), and the CD4 + T cell population also increased (Fig. 2e ).

The CD8 + T cell population in the group treated with the iron-rich iron-rich milk protein (Fe-WPS) showed an increase tendency as compared with the group treated with the WPS alone (FIG. 3D) ).

5) IL-1β and TNF-α secretion of macrophages

As a result of the secretion amount of TNF-a and IL-1b, which are cytokines expressed in macrophages of mice administered with calcium-enriched calcium-enriched milk protein (Ca-WPS), mice treated with calcium- The amount of cytokine secretion tended to be higher than that of the group administered only WPS, but did not show a significant increase (Fig. 1f).

The amount of cytokine TNF-a and IL-1b secretion was significantly increased in mice treated with copper-enriched copper-rich milk protein (Cu-WPS) or mice treated with WPS only (FIG. 2f).

The secretion of cytokines TNF-a and IL-1b was significantly increased in the group treated with the iron-rich iron-rich milk protein (Fe-WPS) and the group treated with WPS alone (FIG.

The formulation examples of the present invention are described below, but are for the purpose of illustration only and not for purposes of limitation of the present invention.

≪ Formulation Example 1 > Preparation of pharmaceutical preparation

1-1. Manufacture of Powder

500 mg of the organotin-coated copper-enriched milk protein of Preparation Example 1

Lactose 100 mg

10 mg of talc

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

500 mg of the organo-iron-enriched milk protein of Preparation Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg of magnesium stearate

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Manufacture of capsules

500 mg of the organotin-coated copper-enriched milk protein of Preparation Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg of magnesium stearate

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Production Example 2: Preparation of health functional food (powder type)

1000 mg of the organotin-iron-fortified milk protein of Preparation Example 1

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg of vitamin

0.15 mg of vitamin B ₂

0.5 mg of vitamin B ₆

Vitamin B ₁₂ 0.2 g

10 mg vitamin C

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 mg of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

24.8 mg of magnesium chloride

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Production Example 3: Preparation of health functional foods (beverage type)

1000 mg of the organotin-coated copper-enriched milk protein of Preparation Example 1

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to a total of 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered and sterilized in a sterilized 2 liter container, And used for manufacturing.

Although the composition ratio is relatively mixed with the ingredient suitable for the favorite drink, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand class, demand country, use purpose, and the like.

Production Example 4: Preparation of health functional foods (chewing gum)

Gum base 20%

Sugar 76.36 ~ 76.76%

The iron oxide-enriched milk protein of Production Example 1 0.24 to 0.64%

Fruit flavor 1%

Water 2%

Chewing gum was prepared using the above-mentioned composition and content by a conventional method.

Preparation Example 5: Preparation of health functional foods (wheat flour foods)

0.5 to 5 parts by weight of the organotin-modified copper-enriched milk protein of Preparation Example 1 was added to 100 parts by weight of wheat flour, and bread, cake, cookies, crackers and noodles were prepared using this mixture to prepare health improving foods.

Manufacturing example  6: Manufacture of functional foods (dairy products)

5 to 10 parts by weight of the iron oxide-enriched milk protein of Preparation Example 1 were added to 100 parts by weight of milk and various dairy products such as butter and ice cream were prepared using the milk.

Claims (5)

delete delete delete delete Powder mixing the whey powder and the aqueous sulfate or chloride powder of iron or iron; And adding water to the mixed powder and heating the mixture at 70 to 100 ° C for 10 minutes to 40 hours to prepare an iron-enriched copper or iron-rich protein having immunity enhancing activity.

Images